Jill Fredrickson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jill Fredrickson has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Sravanthi Cheeti
22Developmental Science Clinical Pharmacology, Genentech, South San Francisco, California
89 shared publications - Aditya Bardia
University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, USA
86 shared publications - Ching-Wei Chang
19PHC and Early Development Oncology Biostatistics, Genentech, Inc., South San Francisco, California
86 shared publications - Heather M. Moore
Translational Medicine – Oncology, Genentech, South San Francisco, USA
86 shared publications - Jose Alejandro Perez Fidalgo
Department of Medical Oncology, University Clinic Hospital of Valencia, 46010 Valencia, Spain
86 shared publications - Mary Gates
Early Clinical Development, Genentech, Inc., South San Francisco, California
86 shared publications
Latest Publications
- Open Access
- 17 October 2026
- Published by Elsevier in JHEP Reports
Phase 2 study of fazpilodemab, a FGFR1/Klothoβ agonist, in metabolic dysfunction-associated steatohepatitis (MASH)
- 17 October 2026
- Published by Elsevier in JHEP Reports
Open AccessPhase 2 study of fazpilodemab, a FGFR1/Klothoβ agonist, in metabolic dysfunction-associated steatohepatitis (MASH)
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Effect of FGFR2-selective inhibitor and non-selective inhibitor infigratinib on normalized growth and downstream FGFR signaling
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Effect of FGFR2-selective inhibitor and non-selective inhibitor infigratinib on normalized growth and downstream FGFR signaling
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
FGFR2 alterations co-occur with PIK3CAmut in breast tumors
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
FGFR2 alterations co-occur with PIK3CAmut in breast tumors
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Evaluation of the anti-tumor activity of FGFR2 inhibitor in combination with inavolisib in MFM223x2.2 xenograft model
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Evaluation of the anti-tumor activity of FGFR2 inhibitor in combination with inavolisib in MFM223x2.2 xenograft model
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Growth rate inhibition metrics
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Growth rate inhibition metrics
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Foundation Medicine (FMI) FoundationACT (FACT) panel of NGS features selected by model as associated with response
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Foundation Medicine (FMI) FoundationACT (FACT) panel of NGS features selected by model as associated with response
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Drug combination effect of inavolisib and the FGFR2i as measured by a two-way 10 x 8 serial dilution matrix in a 5-day viability assay
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Drug combination effect of inavolisib and the FGFR2i as measured by a two-way 10 x 8 serial dilution matrix in a 5-day viability assay
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Relationship between FGFR2 expression and inavolisib sensitivity and pAKT S473 baseline expression
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Relationship between FGFR2 expression and inavolisib sensitivity and pAKT S473 baseline expression
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Prevalence of FGFR2 alterations in conjunction with single and multiple PIK3CAmut breast and pan-solid tumor tissue biopsies
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Prevalence of FGFR2 alterations in conjunction with single and multiple PIK3CAmut breast and pan-solid tumor tissue biopsies